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Background: This study was designed to assess serum vitamin D status (25-OHD) in the fibromyalgia (FM) 
patients and to compare it with a healthy control group. It also aimed to investigate the correlation of serum 
vitamin D level with FM symptom severity and invalidation experiences. 
Methods: A total of 74 consecutive patients with FM and 68 healthy control participants were enrolled. The 
eligible FM patients completed the Illness Invalidation Inventory (3*I), the Revised Fibromyalgia Impact 
Questionnaire (FIQR) and a short-form health survey (SF-12). Venous blood samples were drawn from all 
participants to evaluate serum 25-OHD levels. Mann-Whitney tests and multiple logistic regression analyses 
were performed and Spearman’s correlations were calculated.
Results: 88.4% of FM patients had low levels of serum 25-OHD. FM patients had significantly higher level 
of serum 25-OHD than the control group (17.24 ± 13.50 and 9.91 ± 6.47 respectively, P = 0.0001). There 
were no significant correlations between serum 25-OHD levels and the clinical measures of disease impact, 
invalidation dimensions, and health status. Multiple logistic regression analyses revealed that an increased 
discounting of the disease by the patient’s spouse was associated with a 4-fold increased risk for vitamin D 
deficiency (OR = 4.36; 95% CI, 0.95−19.87, P = 0.05). 
Conclusions: This study showed that although high rates of vitamin D insufficiency or deficiency were seen 
among FM patients and healthy non-FM participants, but it seems there was no intrinsic association between 
FM and vitamin D deficiency. Addressing of invalidation experience especially by the patient’s spouse is 
important in management of FM. (Korean J Pain 2016; 29: 172-8)
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INTRODUCTION
It is proven that vitamin D deficiency can causes clas-
sic musculoskeletal disease such as osteomalacia and 
myopathy [1]. But how can vitamin D deficiency can leads 
to chronic nonspecific pain and FM is not clear. Recent 
case control studies and one systematic review shows that 
there is no difference in serum vitamin D levels between 
healthy persons and Fibromyalgia patients [2-5], but some 
other studies [6-8] reported that chronic widespread pain 
is associated with lower levels of serumic calciferol.
Without considering the pain, vitamin D levels can af-
fect other FM symptoms such as anxiety, depression and 
sleep disorders [9-11]. Recent studies demonstrate a role 
for calciferol deficiency in the development of symptoms of 
wake impairment commonly associated with sleep dis-
orders [11]. As already defined, the relationship between 
pain and psychiatric disorders, as well as sleep disorders, 
in FM is complex and bidirectional [12,13]. Distress and 
sleep disorders can be both a cause and consequence of 
pain. Increased pain perception associated with sleep dep-
rivation reportedly is associated with increased IL-6, an 
inflammatory marker also known to be elevated in patients 
with low 25OHD [11,14].
On the other hand, because these symptoms have a 
subjective nature and they don’t have physical or labo-
ratory features in FM, patients can understand disbelief 
and mistrust about the rightfulness of their illness in family 
and/or social interactions. This situation was recently 
termed as ‘invalidation’ [15]. In lots of these cases, co-
morbidities destroy the patient’s quality of life significantly, 
and also end in unemployment and isolation from social 
life. So, invalidation leads to maladaptive illness behaviors, 
including withdrawal from social life, ceasing of pleasurable 
activities, and a decrease in activity and exercise [15,16]. 
Consequently, it can potentially decrease outdoor activity 
and increases risk for hypovitaminosis D.
This investigation aimed to assess serum vitamin D 
status in Iranian FM patients and compare it to a healthy 
control group. It also intended to evaluate the correlation 
of serum vitamin D level with FM symptoms and invalid-
ation experience in FM patients. 
MATERIALS AND METHODS
This cross-sectional study was carried out in the 
rheumatology outpatient clinic of a teaching hospital in 
Rasht, Iran from April 2013 to September 2013. All con-
secutive subjects of study aged between 18-65 years old 
were enrolled into two groups: FM and non-FM healthy 
groups. For the sake of avoiding confounding factors, we 
selected only female individuals in both groups. Fibromyalgia 
was diagnosed by an expert rheumatologist using American 
College of Rheumatology (ACR) 1990 classification criteria 
or ACR 2010 preliminary criteria [17-19]. Healthy partic-
ipants, however, were selected from volunteer healthy 
members of the FM patients’ families. Of note, these 
healthy participants were all gender-matched and met age 
inclusion criteria.
Patients were excluded if they had rheumatoid arthritis 
or other rheumatologic diseases, severe depression, hy-
perparathyroidism, hyperthyroidism, osteomalacia, osteo-
porosis, liver or renal disease, malabsorption, calcium or 
vitamin D metabolic disorder, diabetes mellitus, malig-
nancy or pregnancy, or were administered anti-depressive 
and anticonvulsants drugs for the last 6 weeks, calcium or 
vitamin D supplements during past 3 months, systemic 
corticosteroids, or were unable to read or write. 
All participants were asked to fill out the demographic 
characteristics form, the Illness Invalidation Inventory (3*I), 
the Revised Fibromyalgia Impact Questionnaire (FIQR) and 
a short-form health survey (SF-12) [20-23]. Then, the FM 
patients underwent dolorimetery examination for evalua-
tion of tender point counts.
Then, the participants were referred to the hospital 
laboratory to take a blood sample. A 5 ml blood sample 
was drawn from an anti-cubital vein from all participants 
in a fasting state. Erythrocyte sedimentation rate, serum 
phosphorus and calcium, and alkaline phosphatase were 
measured with routine laboratory methods in the all 
participants. Serum 25-hydroxyvitamin D3 (25-OHD) lev-
els were measured by using a commercially available 
chemiluminescence Immunoassay (CLIA) Kit (Liaison 25OH 
vitamin D total assay from DiaSorin company).
According to the literature review [1], we considered 
the following cut off points for 25-OHD level: equal or 
more than 30 ng/ml as a normal range, 20-30 ng/ml as 
insufficiency, equal or less than 20 ng/ml as deficiency.
Written informed consent was obtained from all the 
patients. This study was approved by the Local Ethics 
Committee.
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`1. Instruments
1) The Illness Invalidation Inventory (3*I)
Invalidation was measured by the Illness Invalidation 
Inventory (3*I) [21]. This inventory includes eight items 
(discounting [five items] and lack of understanding [three 
items]) assessing the extent to which people experience 
invalidation with regard to each of the five sources 
(spouse, family, medical professionals, work environment, 
and social services). Participants indicated on a 5-point 
scale (1 = never, 2 = seldom, 3 = sometimes, 4 = often, 
5 = very often) how often during the past year people 
within each category reacted to them in the described way. 
A source category that did not apply (e.g., because the 
patient was not employed) was skipped.
2) The Revised Fibromyalgia Impact Questionnaire (FIQR)
In our study, the clinical severity and progress of FM 
was assessed by the validated Persian version of the FIQR 
[23]. This questionnaire has 21 individual questions. All 
questions are based on an 11-point numeric rating scale 
of 0-10 with “10” denoting the ‘worst’. The FIQR is divided 
into three linked sets of domains as in the original FIQ: 
(a) “function” containing 9 questions, (b) “overall impact” 
(2 questions with new questions being related to the overall 
impact of FM on individuals’ function and symptom se-
verity, and (c) “symptoms” (containing 10 questions). The 
summed score is divided by 3 for function (range 0 to 90), 
not changed for overall impact (range 0 to 20), and is div-
ided by 2 for symptoms (range 0 to 100). The total FIQR 
scores would then be the sum of the three modified domain 
scores [20].
3) Medical outcome survey short form 12
Quality of life was assessed by the validated Persian 
version of a short-form health survey (SF-12) including 
eight scales to assess eight dimensions: physical function-
ing, physical role, social role, emotional role, bodily pain, 
general health, vitality and, mental health. Scores range 
from “0 to 100” where “0” indicates the worst and “100” 
the best possible condition [22]. 
4) Tender-point count
Tender-points were identified by applying a dolorim-
eter (Force DialTM FDK20, Wagner, Instrument, EFFEGI, 
Italy) on each of the known anatomical locations. One as-
sessor was trained to correctly performed the dolorimetery 
assessment. Tenderness at any point was considered pres-
ent if some involuntary reaction of the patients to pain was 
observed when its pressure was lower than 4 kg/cm. The 
number of these tender points was recorded as the tender 
point count.
2. Statistical analysis
Results were expressed as a mean ± standard devia-
tion or as a number (percentage). Normality of the dis-
tribution of variables was tested by using the one sample 
Kolmogorov- Smirnov test. The Mann-Whitney test was 
used for comparison of vitamin D distribution in patients 
and the control group, and the Spearman’s correlation co-
efficients were calculated to examine the association of the 
severity of the FM (based on the FIQR), Quality of life 
(based on the SF-12) and Invalidation (based on the 3*I) 
with a serum level of 25OHD. Multiple logistic regression 
(probability for stepwise with entry 0.05, removal level = 
0.10, and the Hosmer and Lemeshow test goodness-of-fit 
with P value = 0.999) was used to obtain insight into the 
correlations between variables. Significance level was 
set at P ＜ 0.05 and the whole statistical analysis was 
carried out using SPSS for Windows version 17.0; SPSS, 
Chicago, IL, USA).
RESULTS
Seventy-four FM patients and 68 healthy participants 
were enrolled to study. The mean age of the patients with 
FM was 37.96 ± 9.8 and that of the non-FM control group 
was 32.63 ± 10.1. Demographic, clinical and laboratory 
data of the FM and non-FM control groups are shown in 
Table 1.
All study participants had normal serum calcium, 
phosphorus and alkaline phosphatase. There was no sig-
nificant difference in mean serum phosphorus between the 
FM and non-FM control group. But, although the mean 
serum level of calcium and alkaline phosphatase were in 
normal ranges in both groups, there were significantly 
higher values in the FM patients than in the control group 
(P = 0.005 and 0.017, respectively).
FM patients had significantly higher level of serum 
25-OHD than the control group (17.24 ± 13.50 and 9.91 
± 6.47 respectively, P = 0.0001). Also, the FM group were 
found to have vitamin D deficiency (Serum 25-OHD ≤ 20 
ng/ml) less than the control (69% and 92%, respectively, 
P = 0.001). The shape of distribution and variability of se-
rum 25-OHD and calcium levels in fibromyalgia are shown 
in Fig. 1.
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Table 1. Comparison of Demographic, Clinical and Laboratory Data between FM Patients and Non-FM Healthy Controls
Variables FM patients (n = 74)  Non-FM healthy controls (n = 68) P value
Age (years), mean (SD) 37.96 ± 9.8 32.63 ± 10.1 0.002
Time with symptoms (month), mean (SD) 58.24 ± 38.89 - -
Time since diagnosis (month), mean (SD) 13.23 ± 6.23 - -
Married, n (%) 53 (96) 63 (92) NS
Serum calcium (mg/dl) 9.32 ± 0.35 9.15 ± 0.43 0.005
Serum phosphorus (mg/dl) 3.60 ± 0.47 3.66 ± 0.54 NS
Serum alkaline phosphatase (U/L) 159.9 ± 48.7 142.3 ± 33.5 0.017
ESR 14 ± 9 15 ± 10 NS
Serum 25-OHD (ng/ml) mean (SD) 17.24 ± 13.50 9.91 ± 6.47 0.001
  Serum 25-OHD ≤ 20 ng/ml, n (%) 48 (69.6) 63 (92.6) 0.001
  Serum 25-OHD:20−30 ng/ml, n (%) 13 (18.8) 4 (5.9)
  Serum 25-OHD ≥ 30 ng/ml, n (%)  8 (11.6) 1 (1.5)
Values ± = means ± standard deviation. NS: insignificant, P value: significant at 0.05 level.
Fig. 1. The shape of distribution and variability of serum 25-OHD and Ca levels in fibromyalgia patients and sex matched
healthy controls.
FIQR total, function, overall, and symptom values in 
FM patients, represented as mean ± SD, were 51.8 ± 
17.2, 13.5 ± 6.5, 10.6 ± 6.3, and 27.2 ± 8.0, respectively.
Discounting and lack of understanding scores for each 
source were reported as the average of the scale items. 
Scores for items 3, 5, and 8 were first reversed into the 
direction of lack of understanding. Discounting scores for 
spouse, family, medical professionals, work environment, 
and social services, represented as mean ± SD, were 2.00 
± 0.85, 1.96 ± 0.80, 1.66 ± 0.88, 1.82 ± 0.89, and 1.13 
± 0.18, respectively. 
Similarly, lack of understanding scores for spouse, 
family, medical professionals, work environment and social 
services, represented as mean ± SD, were 1.89 ± 1.11, 
1.60 ± 0.75, 2.36 ± 1.44, 2.02 ± 0.91, and 1.14 ± 0.28, 
respectively. 
Spearman’s correlation coefficients between serum 
25-OHD and various parameters including RFIQ domains, 
invalidation sources and SF-12 subscales are shows in 
Table 2.
Serum 25-OHD was not correlated with the tender 
point count or FIQR scales for pain, fatigue and anxiety. 
Additionally, neither the FIQ domain’s scores nor invalid-
ation scores were correlated with serum 25-OHD. Multiple 
logistic regression analyses between serum 25-OHD and 
the FIQR domains and different sources of invalidation and 
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Table 2. Spearman Correlation Coefficients between 25-OHD and
Other Variables
Variables
25-OHD
r P value
Age  0.184 NS
Time with symptoms,(month) −0.047 NS
Tender point count  −0.194 NS
VAS for pain −0.097 NS
VAS for fatigue  0.063 NS
VAS for anxiety −0.039 NS
FIQR total score −0.093 NS
FIQR function −0.032 NS
FIQR overall −0.031 NS
FIQR symptom −0.081 NS
Invalidation
  Discounting
    Spouse −0.054 NS
    Family  0.049 NS
    Medical professionals −0.222 NS
    Work environment  0.094 NS
    Social services −0.015 NS
  Lack of understanding
    Spouse −0.106 NS
    Family −0.013 NS
    Medical professionals −0.118 NS
    Work environment  0.242 NS
    Social services  0.121 NS
SF-12 health survey items
  PF −0.057 NS
  RP −0.038 NS
  BP  0.185 NS
  GH  0.086 NS
  VT −0.059 NS
  SF  0.043 NS
  RE  0.219 NS
  MH  0.034 NS
PF: physical functioning, RP: role functioning difficulties caused by
physical problems, BP: bodily pain, GH: general health, VT: vitality,
energy, SF: social functioning, RE: role functioning difficulties 
caused by emotional problems, MH: mental health, MP: medical
professionals, SS: social services, WE: work environment, S: 
spouse, F: family, NS: insignificant, P value: significant at 0.05 level.
Table 3. Multiple Logistic Regression Analyses between 25-OHD  
and Other Variables
P value Odds ratio
95% C.I. for OR
Lower Upper
FIQR function 0.046 1.256 1.00 1.57
FIQR overall 0.012 0.682 0.50 0.91
BP 0.047 0.942 0.88 0.99
RE 0.057 0.971 0.94 1.00
Spouse_discounting 0.057 4.361 0.95 19.87
Spouse_lack 0.011 0.188 0.05 0.68
Only these 6 variables were accociated predictors with vitamin D  
deficiency. BP: bodily pain, RE: role functioning difficulties caused 
by emotional problems. P value, significant at 0.05 level.
SF12 subscales revealed that only increasing of discounting 
by the spouse was associated with a 4-fold increased risk 
for vitamin D deficiency (OR = 4.36; 95% CI, 0.95-19.87, 
P = 0.05). Also, the odds ratio of having vitamin D defi-
ciency was 1.25 times higher in cases with a higher RFIQ 
function score (OR = 1.25; 95% CI = 1.00-1.57, P = 0.04) 
(Table 3).
DISCUSSION
Our results showed a high rate of vitamin D in-
sufficiency or deficiency in FM patients and non-FM 
healthy participants (88.4 versus 98.5, respectively). We 
also showed that there was no significant association be-
tween serum 25-OHD level and clinical measures of dis-
ease impact, invalidation dimensions, and health status. 
But, when we analyzed the data using multiple logistic re-
gression method, discounting by the patient’s spouse was 
shown to be a significant predictor of calciferol deficiency 
in patients with FM.
Fibromyalgia is one of the most common diseases re-
sponsible for chronic musculoskeletal pain seen in the gen-
eral population and outpatient rheumatology practice 
[12,19]. In recent years, numerous studies were designed 
to clear an association between a low level of calciferol and 
FM, two conditions that were prevalent and also lead to 
chronic pain. In spite of many efforts, the evidence for an 
association between them is unconvincing; with no pro-
gression in pain when on a vitamin D supplement [2-8,24]. 
Many reports have showed that vitamin D deficiency can 
be implicated in nonspecific chronic pain or FM, and some 
trials have advocated a vitamin D supplement for treatment 
of FM [6-8,25], but others have not confirmed it 
[2-5,25,26]. Two systematic reviews were performed, both 
of them concluded that the evidence base for the con-
tribution of vitamin D deficiency to FM and using a vitamin 
D supplement for treatment is rather poor [6,27]. de 
Rezende Pena et al. [2] found no statistically significant 
difference between the FM and control groups with respect 
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to mean serum concentration of 25-OHD and no correla-
tion between vitamin D level and pain intensity. Similar re-
sults published by Warner and Arnspiger [5] and also 
Straube et al. [27] who didn’t confirm the link between vi-
tamin D deficiency and chronic pain or FM. 
Our result demonstrated that a low level of 25-OHD 
was not seen more in FM patients, and it was not corre-
lated with pain, or severity of FM, or poor quality of life 
in patients. This is in line with the idea that there is no 
real association between vitamin D deficiency and FM, and 
any observed association could be potentially explained by 
other mechanisms such as less sun exposure in chronic 
disease or associated comorbidities, such as mood 
disorders.
We found low levels of vitamin D in nearly all of the 
healthy control group, which was much higher than that 
seen in other studies [4,5,21]. Also, somewhat more sur-
prising was the higher level of serum 25OHD in the FM 
group than in the healthy subjects. One possibility seems 
plausible. As FM patients have more pain, they are more 
likely to consume vitamin D supplements, which are easily 
accessible as the over the counter medications. Such 
self-treatment may be easily ignored by patients during 
the time of recall for this study. 
Invalidation is a new definition and research on it is 
very scarce. This occurs in syndromes having inherent in-
visibility of symptoms while lacking a clear pathological 
basis such as in FM. It was clearly demonstrated that in-
validation perceived by patients may lead to poor quality 
of life and FM severity in these patients [28]. 
Consequently, it can potentially limit social and outdoor 
activity and can lead to hypovitaminosis D. 
Notable is that although there was no link between low 
level of serum 25OHD and clinical measures of FM severity 
or quality of life in patients, discounting by the patient’s 
spouse was a significant predictor of vitamin D deficiency. 
Discounting by their spouse had a stronger negative im-
pact on social and physical functioning, as well as the im-
pairment of mental health, most strongly rather than other 
invalidation aspects [16]. It is the one aspect of invalidation 
among the various sources of its experience that seems 
to have a higher impact on patients [16]. It could be ex-
pected that patients and their spouses shared daily life ex-
periences, thoughts, and feelings, and had more empathy 
[28]. We showed that for each increase in discounting by 
the spouse, the probability of vitamin D deficiency rose 4.3 
times in FM patients. It is a striking finding which demon-
strates importance of addressing of invalidation experience 
especially by the spouse in management of these patients.
Some limitations of our study are discussed in the 
following. Only female patients were evaluated, and Thus, 
the results of this investigation cannot be extrapolated to 
the opposite sex. The FM patients were a little older than 
the non-FM control subjects, but this doesn’t seem to be 
clinically significant. Moreover, we didn’t study our pa-
tients in a primary care setting. Therefore, they probably 
do not reflect the general population of fibromyalgia 
patients. Furthermore, our patients were not employed; So, 
interpretation of the results of these domains must be 
made with caution. It also needs to be pointed out that 
in our study psychiatric disorders were not studied and that 
they could affect invalidation and vitamin D status.
To sum up, high rates of vitamin D insufficiency or de-
ficiency among FM subjects and non-FM healthy partic-
ipants were seen, but it seems there is no intrinsic associ-
ation between FM and vitamin D deficiency, so that any 
observed associations may be related to other factors that 
coexist with this disease such as lifestyle difference and 
mood disorders. This is the first study that tried to eval-
uate the correlation between serum vitamin D level and in-
validation dimensions in FM patients. It is important to 
note and evaluate the invalidation perceptions by FM pa-
tients, especially toward their spouse, with regard to as-
sessment and treatment of FM. 
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